Ephedrine Explained

Ephedrine is a central nervous system (CNS) stimulant and sympathomimetic agent that is often used to prevent low blood pressure during anesthesia.[1] It has also been used for asthma, narcolepsy, and obesity but is not the preferred treatment.[1] It is of unclear benefit in nasal congestion.[1] It can be taken by mouth or by injection into a muscle, vein, or just under the skin.[1] Onset with intravenous use is fast, while injection into a muscle can take 20minutes, and by mouth can take an hour for effect.[1] When given by injection, it lasts about an hour, and when taken by mouth, it can last up to four hours.[1]

Common side effects include trouble sleeping, anxiety, headache, hallucinations, high blood pressure, fast heart rate, loss of appetite, and urinary retention.[1] Serious side effects include stroke and heart attack.[1] While likely safe in pregnancy, its use in this population is poorly studied.[2] [3] Use during breastfeeding is not recommended.[3] Ephedrine works by inducing the release of norepinephrine and hence indirectly activating the α- and β-adrenergic receptors.[1] Chemically, ephedrine is a substituted amphetamine and is the (1R,2S)-enantiomer of β-hydroxy-N-methylamphetamine.

Ephedrine was first isolated in 1885 and came into commercial use in 1926.[4] [5] It is on the World Health Organization's List of Essential Medicines.[6] It is available as a generic medication.[1] It can normally be found in plants of the Ephedra genus.[7] Over-the-counter dietary supplements containing ephedrine are illegal in the United States, with the exception of those used in traditional Chinese medicine, where its presence is noted by má huáng.[1]

Medical uses

Ephedrine is a non-catecholamine sympathomimetic with cardiovascular effects similar to those of adrenaline/epinephrine: increased blood pressure, heart rate and contractility. Like pseudoephedrine it is a bronchodilator, with pseudoephedrine having considerably less effect.[8] [9]

Ephedrine may decrease motion sickness, but it has mainly been used to decrease the sedating effects of other medications used for motion sickness.[10] [11]

Ephedrine is also found to have quick and long-lasting responsiveness in congenital myasthenic syndrome in early childhood and also even in the adults with a novel COLQ mutation.[12]

Ephedrine is administered by intravenous boluses. Redosing usually requires increased doses to offset the development of tachyphylaxis, which is attributed to the depletion of catecholamine stores.[8]

Weight loss

Ephedrine promotes modest short-term weight loss,[13] specifically fat loss, but its long-term effects are unknown.[14] In mice, ephedrine is known to stimulate thermogenesis in the brown adipose tissue, but because adult humans have only small amounts of brown fat, thermogenesis is assumed to take place mostly in the skeletal muscle. Ephedrine also decreases gastric emptying. Methylxanthines such as caffeine and theophylline have a synergistic effect with ephedrine with respect to weight loss. This led to creation and marketing of compound products.[15] One of them, known as the ECA stack, contains ephedrine with caffeine and aspirin. It is a popular supplement taken by bodybuilders seeking to cut body fat before a competition.[16] A 2021 systematic review found that ephedrine led to a weight loss greater than placebo, raised heart rate, and reduced LDL and raised HDL, with no statistically significant difference in blood pressure.[17]

Available forms

See also: Theophylline/ephedrine.

Ephedrine is available as a prescription-only pharmaceutical drug in the form of an intravenous solution, under brand names including Akovaz, Corphedra, Emerphed, and Rezipres as well as in generic forms, in the United States.[18] [19] It is also available over-the-counter in the form of 12.5 and 25mg oral tablets for use as a bronchodilator and as a 0.5% concentration nasal spray for use as a decongestant. The drug is additionally available in combination with guaifenesin in the form of oral tablets and liquids. Ephedrine is provided as the hydrochloride or sulfate salt in pharmaceutical formulations.

Contraindications

Ephedrine should not be used in conjunction with certain antidepressants, namely norepinephrine-dopamine reuptake inhibitors (NDRIs), as this increases the risk of symptoms due to excessive serum levels of norepinephrine.

Bupropion is an example of an antidepressant with an amphetamine-like structure similar to ephedrine, and it is an NDRI. Its action bears more resemblance to amphetamine than to fluoxetine in that its primary mode of therapeutic action involves norepinephrine and to a lesser degree dopamine, but it also releases some serotonin from presynaptic clefts. It should not be used with ephedrine, as it may increase the likelihood of side effects.

Ephedrine should be used with caution in patients with inadequate fluid replacement, impaired adrenal function, hypoxia, hypercapnia, acidosis, hypertension, hyperthyroidism, prostatic hypertrophy, diabetes mellitus, cardiovascular disease, during delivery if maternal blood pressure is >130/80 mmHg, and during lactation.[20]

Contraindications for the use of ephedrine include: closed-angle glaucoma, phaeochromocytoma, asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis), concomitant or recent (previous 14 days) monoamine oxidase inhibitor (MAOI) therapy, general anaesthesia with halogenated hydrocarbons (particularly halothane), tachyarrhythmias or ventricular fibrillation, or hypersensitivity to ephedrine or other stimulants.

Ephedrine should not be used at any time during pregnancy unless specifically indicated by a qualified physician and only when other options are unavailable.

Side effects

Ephedrine is a potentially dangerous natural compound; the US Food and Drug Administration had received over 18,000 reports of adverse effects in people using it.

Adverse drug reactions (ADRs) are more common with systemic administration (e.g. injection or oral administration) compared to topical administration (e.g. nasal instillations). ADRs associated with ephedrine therapy include:[21]

Overdose

Overdose of ephedrine may result in sympathomimetic symptoms like tachycardia and hypertension.

Interactions

Ephedrine with monoamine oxidase inhibitors (MAOIs) like phenelzine and tranylcypromine can result in hypertensive crisis.

Pharmacology

Pharmacodynamics

Monoamine release by ephedrine and related agents (nM)[22] [23]
Compound data-sort-type="number" !data-sort-type="number" !data-sort-type="number" !Ref
Dextroamphetamine (S(+)-amphetamine) 6.6–7.2 5.8–24.8 698–1765 [24] [25]
12.4 18.5 2366 [26]
Ephedrine ((–)-ephedrine) 43.1–72.4 236–1350 >10000
(+)-Ephedrine 218 2104 >10000
Dextromethamphetamine (S(+)-methamphetamine) 12.3–13.8 8.5–24.5 736–1291.7 [27]
Levomethamphetamine (R(–)-methamphetamine) 28.5 416 4640
(+)-Phenylpropanolamine ((+)-norephedrine) 42.1 302 >10000
(–)-Phenylpropanolamine ((–)-norephedrine) 137 1371 >10000
Cathine ((+)-norpseudoephedrine) 15.0 68.3 >10000
30.1 294 >10000
(–)-Pseudoephedrine 4092 9125 >10000
Pseudoephedrine ((+)-pseudoephedrine) 224 1988 >10000
Notes: The smaller the value, the more strongly the substance releases the neurotransmitter. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds.

Ephedrine, a sympathomimetic amine, acts on part of the sympathetic nervous system (SNS). The principal mechanism of action relies on its indirect stimulation of the adrenergic receptor system by increasing activation of α- and β-adrenergic receptors via induction of norepinephrine release.[28] The presence of direct interactions with α-adrenergic receptors is unlikely, but still controversial.[9] [29] [30] L-ephedrine, and particularly its stereoisomer norpseudoephedrine (which is also present in Catha edulis) has indirect sympathomimetic effects and due to its ability to cross the blood–brain barrier, it is a CNS stimulant similar to amphetamines, but less pronounced, as it releases norepinephrine and dopamine in the brain.[31]

Pharmacokinetics

Absorption

The oral bioavailability of ephedrine is 88%. The onset of action of ephedrine orally is 15 to 60minutes, via intramuscular injection is 10 to 20minutes, and via intravenous infusion is within seconds.

Distribution

Its plasma protein binding is approximately 24 to 29%, with 5 to 10% bound to albumin.

Metabolism

Ephedrine is largely not metabolized. Norephedrine (phenylpropanolamine) is an active metabolite of ephedrine formed via N-demethylation. About 8 to 20% of an oral dose of ephedrine is demethylated into norephedrine, about 4 to 13% is oxidatively deaminated into benzoic acid, and a small fraction is converted into 1,2-dihydroxy-1-phenylpropane.

Elimination

Ephedrine is eliminated mainly in urine, with 60% (range 53–79%) excreted unchanged.

The elimination half-life of ephedrine is 6hours. Its duration of action orally is 2 to 4hours and via intravenous or intramuscular injection is 60minutes.

The elimination of ephedrine is dependent on urinary pH.

Chemistry

Ephedrine, or (−)-(1R,2S)-ephedrine, also known as (1R,2S)-β-hydroxy-N-methyl-α-methyl-β-phenethylamine or as (1R,2S)-β-hydroxy-N-methylamphetamine, is a substituted phenethylamine and amphetamine derivative. It is similar in chemical structure to phenylpropanolamine, methamphetamine, and epinephrine (adrenaline). It differs from methamphetamine only by the presence of a hydroxyl group (–OH). Chemically, ephedrine is an alkaloid with a phenethylamine skeleton found in various plants in the genus Ephedra (family Ephedraceae). It is most usually marketed as the hydrochloride or sulfate salt.

It has an experimental log P of 1.13, while its predicted log P values range from 0.9 to 1.32.[32] [33] The lipophilicity of amphetamines is closely related to their brain permeability.[34] For comparison to ephedrine, the experimental log P of methamphetamine is 2.1,[35] of amphetamine is 1.8,[36] of pseudoephedrine is 0.89,[37] of phenylpropanolamine is 0.7,[38] of phenylephrine is -0.3,[39] and of norepinephrine is -1.2.[40] Methamphetamine has high brain permeability, whereas phenylephrine and norepinephrine are peripherally selective drugs.[41] [42] The optimal log P for brain permeation and central activity is about 2.1 (range 1.5–2.7).[43]

Ephedrine hydrochloride has a melting point of 187−188°C.[44]

The racemic form of ephedrine is racephedrine ((±)-ephedrine; dl-ephedrine; (1RS,2SR)-ephedrine). A stereoisomer of ephedrine is pseudoephedrine. Derivatives of ephedrine include methylephedrine (N-methylephedrine), etafedrine (N-ethylephedrine), cinnamedrine (N-cinnamylephedrine), and oxilofrine (4-hydroxyephedrine). Analogues of ephedrine include phenylpropanolamine (norephedrine) and metaraminol (3-hydroxynorephedrine).

The presence of an N-methyl group decreases binding affinities at α-adrenergic receptors, compared with norephedrine. Ephedrine, though, binds better than N-methylephedrine, which has an additional methyl group at the nitrogen atom. Also the steric orientation of the hydroxyl group is important for receptor binding and functional activity.

Nomenclature

Ephedrine exhibits optical isomerism and has two chiral centres, giving rise to four stereoisomers. By convention, the pair of enantiomers with the stereochemistry (1R,2S) and (1S,2R) is designated ephedrine, while the pair of enantiomers with the stereochemistry (1R,2R) and (1S,2S) is called pseudoephedrine.

The isomer which is marketed is (−)-(1R,2S)-ephedrine.[45]

In the outdated D/L system (+)-ephedrine is also referred to as D-ephedrine and (−)-ephedrine as L-ephedrine (in which case, in the Fisher projection, the phenyl ring is drawn at the bottom).[45] [46]

Often, the D/L system (with small caps) and the d/l system (with lower-case) are confused. The result is that the levorotary l-ephedrine is wrongly named L-ephedrine and the dextrorotary d-pseudoephedrine (the diastereomer) wrongly D-pseudoephedrine.

The IUPAC names of the two enantiomers are (1R,2S)- respectively (1S,2R)-2-methylamino-1-phenylpropan-1-ol. A synonym is erythro-ephedrine.

Detection in body fluids

Ephedrine may be quantified in blood, plasma, or urine to monitor possible abuse by athletes, confirm a diagnosis of poisoning, or assist in a medicolegal death investigation. Many commercial immunoassay screening tests directed at the amphetamines cross-react appreciably with ephedrine, but chromatographic techniques can easily distinguish ephedrine from other phenethylamine derivatives. Blood or plasma ephedrine concentrations are typically in the 20–200μg/L range in persons taking the drug therapeutically, 300–3000μg/L in abusers or poisoned patients and 3–20mg/L in cases of acute fatal overdosage. The current World Anti-Doping Agency (WADA) limit for ephedrine in an athlete's urine is 10μg/mL.[47] [48] [49] [50]

History

Asia

Ephedrine in its natural form, known as máhuáng (麻黄) in traditional Chinese medicine, has been documented in China since the Han dynasty (206 BC – 220 AD) as an antiasthmatic and stimulant.[51] In traditional Chinese medicine, máhuáng has been used as a treatment for asthma and bronchitis for centuries.[52]

In 1885, the chemical synthesis of ephedrine was first accomplished by Japanese organic chemist Nagai Nagayoshi based on his research on traditional Japanese and Chinese herbal medicines.

The industrial manufacture of ephedrine in China began in the 1920s, when Merck began marketing and selling the drug as ephetonin. Ephedrine exports from China to the West grew from 4 to 216 tonnes between 1926 and 1928.[53]

Western medicine

Ephedrine was first introduced for medical use in the United States in 1926.[54]

It was introduced in 1948 in Vicks Vatronol nose drops (now discontinued) which contained ephedrine sulfate as the active ingredient for rapid nasal decongestion.

Society and culture

Names

Ephedrine is the generic name of the drug and its .[55] [56] [57] Its is ephédrine while its is efedrina. In the case of the hydrochloride salt, its generic name is ephedrine hydrochloride and this is its,, and . In the case of the sulfate salt, its generic name is ephedrine sulfate or ephedrine sulphate and the former is its while the latter is its . A synonym of ephedrine sulfate is isofedrol. These names all refer to the (1R,2R)-enantiomer of ephedrine. The racemic form of ephedrine is known as racephedrine and this is its and, while the hydrochloride salt of the racemic form is racephedrine hydrochloride and this is its .[58]

Recreational use

As a phenethylamine, ephedrine has a similar chemical structure to amphetamines and is a methamphetamine analog having the methamphetamine structure with a hydroxyl group at the β position. Because of ephedrine's structural similarity to methamphetamine, it can be used to create methamphetamine using chemical reduction in which ephedrine's hydroxyl group is removed; this has made ephedrine a highly sought-after chemical precursor in the illicit manufacture of methamphetamine.

The most popular method for reducing ephedrine to methamphetamine is similar to the Birch reduction, in that it uses anhydrous ammonia and lithium metal in the reaction. The second-most popular method uses red phosphorus and iodine in the reaction with ephedrine. Moreover, ephedrine can be synthesized into methcathinone via simple oxidation. As such, ephedrine is listed as a table-I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.[59]

Use in exercise and sports

Ephedrine has been used as a performance-enhancing drug in exercise and sports.[60] [61] [62] [63] It can increase heart rate, blood pressure, and cardiac contractility as well as act as a psychostimulant. Ephedrine is often used in combination with caffeine for performance-enhancing purposes.

Other uses

In chemical synthesis, ephedrine is used in bulk quantities as a chiral auxiliary group.[64]

In saquinavir synthesis, the half-acid is resolved as its salt with l-ephedrine.

Legal status

Canada

In January 2002, Health Canada issued a voluntary recall of all ephedrine products containing more than 8mg per dose, all combinations of ephedrine with other stimulants such as caffeine, and all ephedrine products marketed for weight-loss or bodybuilding indications, citing a serious risk to health.[65] Ephedrine is still sold as an oral nasal decongestant[66] in 8mg pills as a natural health product, with a limit of 0.4g (400mg) per package, the limit established by the Controlled Drugs and Substances Act as it is considered as Class A Precursor.[67]

United States

In 1997, the FDA proposed a regulation on ephedra (the herb from which ephedrine is obtained), which limited an ephedra dose to 8mg (of active ephedrine) with no more than 24mg per day.[68] This proposed rule was withdrawn, in part, in 2000 because of "concerns regarding the agency's basis for proposing a certain dietary ingredient level and a duration of use limit for these products."[69] In 2004, the FDA created a ban on ephedrine alkaloids marketed for reasons other than asthma, colds, allergies, other disease, or traditional Asian use.[70] On April 14, 2005, the U.S. District Court for the District of Utah ruled the FDA did not have proper evidence that low dosages of ephedrine alkaloids are actually unsafe,[71] but on August 17, 2006, the U.S. Court of Appeals for the Tenth Circuit in Denver upheld the FDA's final rule declaring all dietary supplements containing ephedrine alkaloids adulterated, and therefore illegal for marketing in the United States.[72] Furthermore, ephedrine is banned by the NCAA, MLB, NFL, and PGA.[73] Ephedrine is, however, still legal in many applications outside of dietary supplements. Purchasing is currently limited and monitored, with specifics varying from state to state.

The House passed the Combat Methamphetamine Epidemic Act of 2005 as an amendment to the renewal of the USA PATRIOT Act. Signed into law by President George W. Bush on March 6, 2006, the act amended the US Code (21 USC 830) concerning the sale of products containing ephedrine and the closely related drug pseudoephedrine. Both substances are used as precursors in the illicit production of methamphetamine, and to discourage that use the federal statute included the following requirements for merchants who sell these products:

The law gives similar regulations to mail-order purchases, except the monthly sales limit is 7.5g.

As a pure herb or tea, má huáng, containing ephedrine, is still sold legally in the US. The law restricts/prohibits its being sold as a dietary supplement (pill) or as an ingredient/additive to other products, like diet pills.

Australia

Ephedrine and all Ephedra species which contain it are considered Schedule 4 substances under the Poisons Standard. A Schedule 4 drug is considered a Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription under the Poisons Standard.

South Africa

In South Africa, ephedrine was moved to schedule 6 on 27 May 2008,[74] which makes pure ephedrine tablets prescription only. Pills containing ephedrine up to 30mg per tablet in combination with other medications are still available OTC, schedule 1 and 2, for sinus, head colds and influenza.

Germany

Ephedrine was freely available in pharmacies in Germany until 2001. Afterwards, access was restricted since it was mostly bought for unindicated uses. Similarly, ephedra can only be bought with a prescription. Since April 2006, all products, including plant parts, that contain ephedrine are only available with a prescription.[75]

Sources

Agricultural

Ephedrine is obtained from the plant Ephedra sinica and other members of the genus Ephedra, from which the name of the substance is derived. Raw materials for the manufacture of ephedrine and traditional Chinese medicines are produced in China on a large scale. As of 2007, companies produced for export US$13 million worth of ephedrine from 30,000 tons of ephedra annually, or about ten times the amount used in traditional Chinese medicine.[76]

Synthetic

Most of the l-ephedrine produced today for official medical use is made synthetically as the extraction and isolation process from E. sinica is tedious and no longer cost effective.[77]

Biosynthetic

Ephedrine was long thought to come from modifying the amino acid L-phenylalanine.[78] L-Phenylalanine would be decarboxylated and subsequently attacked with ω-aminoacetophenone. Methylation of this product would then produce ephedrine. This pathway has since been disproven.[78] A new pathway proposed suggests that phenylalanine first forms cinnamoyl-CoA via the enzymes phenylalanine ammonia-lyase and acyl CoA ligase. The cinnamoyl-CoA is then reacted with a hydratase to attach the alcohol functional group. The product is then reacted with a retro-aldolase, forming benzaldehyde. Benzaldehyde reacts with pyruvic acid to attach a 2 carbon unit. This product then undergoes transamination and methylation to form ephedrine and its stereoisomer, pseudoephedrine.

Notes and References

  1. Web site: Ephedrine. The American Society of Health-System Pharmacists. 8 September 2017 . live. https://web.archive.org/web/20170909053108/https://www.drugs.com/monograph/ephedrine.html. 2017-09-09.
  2. Book: Briggs GG, Freeman RK, Yaffe SJ . Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk. 2011. Lippincott Williams & Wilkins. Philadelphia. 9781608317080. 495. 9th. live. https://web.archive.org/web/20170908191457/https://books.google.com/books?id=OIgTE4aynrMC&pg=PA495 . 2017-09-08.
  3. Web site: Ephedrine Pregnancy and Breastfeeding Warnings. 8 October 2017. live. https://web.archive.org/web/20170805145931/https://www.drugs.com/pregnancy/ephedrine.html. 5 August 2017.
  4. Book: Soni MG, Shelke K, Amin R, Talati . A Lessons from the Use of Ephedra Products as a Dietary Supplement . Bagchi D, Preuss HG . Obesity epidemiology, pathophysiology, and prevention. 2013. CRC Press. Boca Raton, Florida. 9781439854266. 692. 2nd. https://books.google.com/books?id=6oHRBQAAQBAJ&pg=PA692. live. https://web.archive.org/web/20170908191457/https://books.google.com/books?id=6oHRBQAAQBAJ&pg=PA692. 2017-09-08.
  5. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 541 .
  6. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  7. Abourashed EA, El-Alfy AT, Khan IA, Walker L . 41083359 . Ephedra in perspective—a current review . Phytotherapy Research . 17 . 7 . 703–712 . August 2003 . 12916063 . 10.1002/ptr.1337 .
  8. Book: Butterworth IV JF, Mackey DC, Wasnick JD . Chapter 14. Adrenergic Agonists & Antagonists. . Morgan & Mikhail's Clinical Anesthesiology . 7th . 2022 . McGraw-Hill Education . https://accessanesthesiology.mhmedical.com/content.aspx?bookid=3194&sectionid=266518784 . 978-1-260-47379-7 .
  9. Drew CD, Knight GT, Hughes DT, Bush M . Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man . British Journal of Clinical Pharmacology . 6 . 3 . 221–5 . September 1978 . 687500 . 1429447 . 10.1111/j.1365-2125.1978.tb04588.x .
  10. Book: Buckey Jr JC . Space Physiology . 2006 . Oxford University Press . 978-0-1997-4790-0 . 201 .
  11. Book: Sanford CA, Jong EC . The Travel and Tropical Medicine Manual E-Book . 2008 . Elsevier Health Sciences . 978-1437710694 . 139 .
  12. Higashida K, Yamada M, Shimohata T . 2021-04-13. Quick and long-lasting responsiveness by ephedrine in an adult woman with congenital myasthenic syndrome associated with a novel COLQ mutation. (2928) . Neurology. 96. 15 Supplement. 10.1212/WNL.96.15_supplement.2928 . 266124150 . 0028-3878.
  13. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J . 6 . Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis . JAMA . 289 . 12 . 1537–45 . March 2003 . 12672771 . 10.1001/jama.289.12.1470 .
  14. Dwyer JT, Allison DB, Coates PM . Dietary supplements in weight reduction . Journal of the American Dietetic Association . 105 . 5 Suppl 1 . S80-6 . May 2005 . 15867902 . 10.1016/j.jada.2005.02.028 .
  15. Book: Bray GA, Bouchard C . Handbook of obesity . 2004 . CRC Press . 978-0-8247-4773-2 . 494–496 . live . https://web.archive.org/web/20140626190101/http://books.google.com/books?id=YVQPOfKYJhUC&pg=PA494 . 2014-06-26.
  16. Magkos F, Kavouras SA . Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects . Sports Medicine . 34 . 13 . 871–89 . 2004 . 15487903 . 10.2165/00007256-200434130-00002 . 1966020 .
  17. Yoo HJ, Yoon HY, Yee J, Gwak HS . Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials . Pharmaceuticals . 14 . 11 . 1198 . November 2021 . 34832979 . 8618781 . 10.3390/ph14111198 . free .
  18. Web site: Drugs@FDA: FDA-Approved Drugs . Food and Drug Administration . accessdata.fda.gov . 14 July 2024.
  19. Web site: Search Results for ephedrine . DailyMed . 14 July 2024.
  20. Mayne Pharma. Ephedrine sulfate injection DBL (Approved Product Information). Melbourne: Mayne Pharma; 2004
  21. Joint Formulary Committee. British National Formulary, 47th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004.
  22. Rothman RB, Baumann MH . Monoamine transporters and psychostimulant drugs . Eur. J. Pharmacol. . 479 . 1–3 . 23–40 . 2003 . 14612135 . 10.1016/j.ejphar.2003.08.054.
  23. Rothman RB, Baumann MH . Therapeutic potential of monoamine transporter substrates . Curr Top Med Chem . 6 . 17 . 1845–1859 . 2006 . 17017961 . 10.2174/156802606778249766 .
  24. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS . Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin . Synapse . 39 . 1 . 32–41 . January 2001 . 11071707 . 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 .
  25. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW . Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products . Neuropsychopharmacology . 38 . 4 . 552–562 . 2013 . 23072836 . 3572453 . 10.1038/npp.2012.204 .
  26. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA . In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates . J Pharmacol Exp Ther . 307 . 1 . 138–145 . October 2003 . 12954796 . 10.1124/jpet.103.053975 .
  27. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV . The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue . Neuropsychopharmacology . 37 . 5 . 1192–203 . April 2012 . 22169943 . 3306880 . 10.1038/npp.2011.304 .
  28. Web site: EPHEDrine . January 2010 . Merck Manuals . https://web.archive.org/web/20110324031411/http://www.merckmanuals.com/professional/lexicomp/ephedrine.html . 24 March 2011 .
  29. Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, Khan IA, Feller DR . 6 . Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes . The Journal of Pharmacology and Experimental Therapeutics . 322 . 1 . 214–221 . July 2007 . 17405867 . 10.1124/jpet.107.120709 . 86429875 .
  30. Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y, Gando S . 6 . The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? . Anesthesia and Analgesia . 97 . 5 . 1239–1245 . November 2003 . 14570629 . 10.1213/01.ANE.0000092917.96558.3C . free .
  31. Munhall AC, Johnson SW . Dopamine-mediated actions of ephedrine in the rat substantia nigra . Brain Research . 1069 . 1 . 96–103 . January 2006 . 16386715 . 10.1016/j.brainres.2005.11.044 . 40626692 .
  32. Web site: Ephedrine . PubChem . 30 August 2024.
  33. Web site: L-(−)-Ephedrine . ChemSpider . 30 August 2024 . 30 August 2024.
  34. Bharate SS, Mignani S, Vishwakarma RA . Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis . J Med Chem . 61 . 23 . 10345–10374 . December 2018 . 29989814 . 10.1021/acs.jmedchem.7b01922 .
  35. Schep LJ, Slaughter RJ, Beasley DM . The clinical toxicology of metamfetamine . Clin Toxicol (Phila) . 48 . 7 . 675–694 . August 2010 . 20849327 . 10.3109/15563650.2010.516752 . Metamfetamine acts in a manner similar to amfetamine, but with the addition of the methyl group to the chemical structure. It is more lipophilic (Log p value 2.07, compared with 1.76 for amfetamine),4 thereby enabling rapid and extensive transport across the blood–brain barrier.19.
  36. Web site: Amphetamine . PubChem . 26 July 2024.
  37. Web site: Pseudoephedrine . PubChem . 25 July 2024.
  38. Web site: Norephedrine . PubChem . 26 July 2024.
  39. Web site: Phenylephrine . PubChem . 21 July 2024.
  40. Web site: Norepinephrine . PubChem . 26 July 2024.
  41. Eccles R . Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse . British Journal of Clinical Pharmacology . 63 . 1 . 10–14 . January 2007 . 17116124 . 2000711 . 10.1111/j.1365-2125.2006.02833.x .
  42. Froese L, Dian J, Gomez A, Unger B, Zeiler FA . The cerebrovascular response to norepinephrine: A scoping systematic review of the animal and human literature . Pharmacol Res Perspect . 8 . 5 . e00655 . October 2020 . 32965778 . 10.1002/prp2.655 . 7510331 .
  43. Pajouhesh H, Lenz GR . Medicinal chemical properties of successful central nervous system drugs . NeuroRx . 2 . 4 . 541–553 . October 2005 . 16489364 . 1201314 . 10.1602/neurorx.2.4.541 . Lipophilicity was the first of the descriptors to be identified as important for CNS penetration. Hansch and Leo54 reasoned that highly lipophilic molecules will partitioned into the lipid interior of membranes and will be retained there. However, ClogP correlates nicely with LogBBB with increasing lipophilicity increasing brain penetration. For several classes of CNS active substances, Hansch and Leo54 found that blood-brain barrier penetration is optimal when the LogP values are in the range of 1.5-2.7, with the mean value of 2.1. An analysis of small drug-like molecules suggested that for better brain permeation46 and for good intestinal permeability55 the LogD values need to be greater than 0 and less than 3. In comparison, the mean value for ClogP for the marketed CNS drugs is 2.5, which is in good agreement with the range found by Hansch et al.22.
  44. Book: Budavari S . The Merck Index: An encyclopedia of chemicals, drugs, and biologicals . 12th . Whitehouse Station . Merck .
  45. Book: Reynolds JEF . Martindale: The complete drug reference . 29th . 1989 . Pharmaceutical Press . London . 978-0-85369-210-2 . Reynolds J . Martindale: The complete drug reference .
  46. Patil PN, Tye A, Lapidus JB . The Journal of Pharmacology and Experimental Therapeutics . 148 . 2 . 158–68 . May 1965 . 14301006 . A Pharmacological Study of the Ephedrine Isomers .
  47. Web site: S6. Stimulants | List of Prohibited Substances and Methods . 2015-10-19 . dead . https://web.archive.org/web/20151023042222/http://list.wada-ama.org/list/s6-stimulants/ . 2015-10-23 .
  48. Schier JG, Traub SJ, Hoffman RS, Nelson LS . Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level . Journal of Toxicology. Clinical Toxicology . 41 . 6 . 849–53 . 2003 . 14677795 . 10.1081/clt-120025350 . 23359388 .
  49. WADA. The World Anti-Doping Code, World Anti-Doping Agency, Montreal, Canada, 2010. url
  50. Book: Baselt R . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . Foster City, CA . 2008 . 542–544 .
  51. Book: Levy WO, Kalidas K . Miller NS . Principles of Addictions and the Law: Applications in Forensic, Mental Health, and Medical Practice. 26 February 2010. Academic Press. 978-0-12-496736-6. 307–308.
  52. Book: Ford MD, Delaney KA, Ling LJ, Erickson T . Clinical Toxicology . Philadelphia . WB Saunders . 2001 . 0-7216-5485-1.
  53. Book: Dikotter F, Laamann LP . Narcotic Culture: A History of Drugs in China . 16 April 2004 . University of Chicago Press . 978-0-226-14905-9 . 199 .
  54. Palamar J . How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy . Health Policy . 99 . 1 . 1–9 . January 2011 . 20685002 . 10.1016/j.healthpol.2010.07.007 .
  55. Book: Elks, J. . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer US . 2014 . 978-1-4757-2085-3 . 30 August 2024 . 793.
  56. Book: Schweizerischer Apotheker-Verein . Index Nominum: International Drug Directory . Medpharm Scientific Publishers . 2004 . 978-3-88763-101-7 . 30 August 2024 . 450.
  57. Web site: Ephedrine (International database) . Drugs.com . 5 August 2024 . 30 August 2024.
  58. Book: Schweizerischer Apotheker-Verein . Index Nominum 2000: International Drug Directory . Medpharm Scientific Publishers . 2000 . 978-3-88763-075-1 . 30 August 2024 . 390.
  59. http://www.incb.org/pdf/e/list/red.pdf Microsoft Word – RedListE2007.doc
  60. Docherty JR . Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) . Br J Pharmacol . 154 . 3 . 606–622 . June 2008 . 18500382 . 2439527 . 10.1038/bjp.2008.124 .
  61. Lieberman HR . The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood and energy . Nutr Rev . 59 . 4 . 91–102 . April 2001 . 11368507 . 10.1111/j.1753-4887.2001.tb06995.x .
  62. Magkos F, Kavouras SA . Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects . Sports Med . 34 . 13 . 871–889 . 2004 . 15487903 . 10.2165/00007256-200434130-00002 .
  63. Graham TE . Caffeine, coffee and ephedrine: impact on exercise performance and metabolism . Can J Appl Physiol . 26 Suppl . S103–S119 . 2001 . 11897887 .
  64. Borsato G, Linden A, Lucchi OD, Lucchini V, Wolstenholme D, Zambon A . Chiral polycyclic ketones via desymmetrization of dihaloolefins . The Journal of Organic Chemistry . 72 . 11 . 4272–5 . May 2007 . 17474779 . 10.1021/jo070222g . 11380/1138891 .
  65. Web site: Health Canada requests recall of certain products containing Ephedra/ephedrine . . January 9, 2002 . July 7, 2009 . https://web.archive.org/web/20070206073244/http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2002/2002_01_e.html . February 6, 2007.
  66. Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E . Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants . European Annals of Otorhinolaryngology, Head and Neck Diseases . 132 . 1 . 31–4 . February 2015 . 25532441 . 10.1016/j.anorl.2014.11.001 . free .
  67. Web site: Legislative Services Branch. 2021-03-18. Consolidated federal laws of canada, Controlled Drugs and Substances Act. 2021-07-30. laws-lois.justice.gc.ca. 2021-07-30. https://web.archive.org/web/20210730190944/https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-18.html. dead.
  68. https://web.archive.org/web/20080102053737/http://www.cfsan.fda.gov/~lrd/fr97064a.html Federal Register: June 4, 1997 (Volume 62, Number 107): Dietary Supplements Containing Ephedrine Alkaloids; Proposed Rule
  69. https://web.archive.org/web/20080126192127/http://www.cfsan.fda.gov/~lrd/fr00043a.html Federal Register: April 3, 2000 (Volume 65, Number 64): Dietary Supplements Containing Ephedrine Alkaloids; Withdrawal in Part
  70. https://web.archive.org/web/20070929121300/http://www.cfsan.fda.gov/~lrd/fr040211.html Federal Register: February 11, 2004 (Volume 69, Number 28): Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk; Final Rule
  71. Web site: Nutraceutical Corporation; Solaray, Inc., Plaintiffs-appellees, v. Andrew Von Eschenbach, Acting Commissioner, U.S. Food and Drug Administration; United States Food and Drug Administration; Michael O. Leavitt, Secretary of the Department of Health and Human Services; Department of Health and Human Services; United States of America . Defendants-appellants, 459 F.3d 1033 (10th Cir. 2006) . 2010-07-01 . dead . https://web.archive.org/web/20110710194438/http://www.ephedrinehydrochloride.com/204cv409-28.pdf . 2011-07-10 .
  72. Nutraceutical Corporation; Solaray, Inc. Plaintiffs-Appellees vs. Andrew Von Eschenbach, Acting Commissioner, US.. Food and Drug Administration; United States Food and Drug Administration; Michael O. Leavitt, Secretary of the Department of Health and Human Services; Department of Health and Human Services; United States of America . We find that the FDA correctly followed the congressional directive to analyze the risks and benefits of EDS in determining that there is no dosage level of EDS acceptable for the market. . United States Court of Appeals Tenth Circuit . August 17, 2006 . 2007-02-16 . http://www.ck10.uscourts.gov/opinions/05/05-4151.pdf . https://web.archive.org/web/20080921084346/http://www.ck10.uscourts.gov/opinions/05/05-4151.pdf . dead .
  73. Web site: Sport Drug Testing – Drug Programs & Policy – Athletics . 2011-03-21 . dead . https://web.archive.org/web/20110210135236/http://www.drugfreesport.com/drug-resources/faq.asp . 2011-02-10 .
  74. Web site: Rescheduling of Medicines that Contain Ephedrine . 2009-04-18 . dead . https://web.archive.org/web/20090628091843/http://www.doh.gov.za/docs/pr/2008/pr0527.html . 2009-06-28 .
  75. http://www.buzer.de/gesetz/7048/index.htm Verordnung zur Neuordnung der Verschreibungspflicht von Arzneimitteln (AMVVNV).
  76. Web site: Long C . Chinese medicine's great waste of resources . 15 January 2007 . 9 May 2016 . live . https://web.archive.org/web/20160530231517/https://www.chinadialogue.net/article/show/single/en/692-Chinese-medicine-s-great-waste-of-resources . 30 May 2016 .
  77. News: Chemically Synthesized Ephedrine Put into Mass Production in China . November 5, 2001 . live . https://web.archive.org/web/20110629175239/http://english.peopledaily.com.cn/english/200111/05/eng20011105_83931.html . June 29, 2011 .
  78. Participation of C6-C1 unit in the biosynthesis of ephedrine in Ephedra . 10.1016/0031-9422(73)80499-6 . 12 . 12 . Phytochemistry . 2877–2882 . 1973 . Yamasaki K, Tamaki T, Uzawa S, Sankawa U, Shibata S . 1973PChem..12.2877Y .